Loading business workspace…Authorization and release eligibility are being checked.

Portugal – Pharmaceutical products – C/ BASE NO CPA 2024_900 - LAMIVUDINA 300 MG + DOLUTEGRAVIR 50 MG COMP | B2Bounty

B2Bountyby Hiperfusion

Find opportunities Find businesses Plans How sourcing worksSign in For business

Back to opportunities

PUBLIC PROCUREMENT NOTICEExternal opportunity

Preparing English translation…

Portugal – Pharmaceutical products – C/ BASE NO CPA 2024_900 - LAMIVUDINA 300 MG + DOLUTEGRAVIR 50 MG COMP

Aquisição do medicamento LAMIVUDINA 300 MG + DOLUTEGRAVIR 50 MG COMP Aquisição de LAMIVUDINA 300 MG + DOLUTEGRAVIR 50 MG COMP Procedure: restricted. Review the original TED notice for the complete requirement, lots, amendments and attachmen

Opportunity description

Buyer Sign in to view

Response deadline Sign in to view

Delivery Sign in to view

Estimated value Sign in to view

Business details are available after sign in

Codes, capabilities, evidence, buyer details and marketplace actions are withheld from the public HTML and API response.

Create a business account

Public descriptionDetails lockedCreate a business account to unlock released business fields. Protected values are not included in this page.

Open attributed source

The original publisher controls submission. B2Bounty does not automate third-party responses.

Buyer business profileAvailable after sign in

Buyer identity and verification data are not included in the public page payload.

B2Bounty

Contract opportunity intelligence for legal businesses, buyers and partners.

MarketplaceFind opportunities Verified businesses Post an opportunity Plans and access

Trust & sourcingSource attribution Business verification Participation disclosure

Important distinction

B2Bounty is for one legal business hiring or partnering with another. It is not an employment or freelancer marketplace.

Verification reports completed checks; it does not guarantee quality or performance.